Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension.
Mayer KA, Diebold M, Schrezenmeier EV, Halloran PF, Haindl S, Schatzl M, Akifova A, Allmer DM, Schranz S, Kozakowski N, Kläger J, Amann K, Beck J, Schütz E, Naesens M, Loupy A, Raynaud M, Görzer I, Vietzen H, Ingle G, Flesher DL, Patel UD, Halleck F, Graf I, Jilma B, Budde K, Böhmig GA.
Mayer KA, et al. Among authors: schutz e.
Lancet Reg Health Eur. 2026 Jul 9;68:101768. doi: 10.1016/j.lanepe.2026.101768. eCollection 2026 Sep.
Lancet Reg Health Eur. 2026.
PMID: 42471965
Free PMC article.